Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tilogotamab (GEN-1029) is an agonistic hexameric complex targeting two independent epitopes on DR5, used for studying multiple myeloma (MM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $258 | In Stock | |
5 mg | $568 | In Stock | |
10 mg | $910 | In Stock |
Description | Tilogotamab (GEN-1029) is an agonistic hexameric complex targeting two independent epitopes on DR5, used for studying multiple myeloma (MM). |
In vitro | Tilogotamab (20 μg/mL,24h) induced strong cytotoxicity in primary multiple myeloma (MM) cells. [1] |
In vivo | Tilogotamab at a concentration of 20 μg/mL for 24 hours exhibits potent cytotoxicity against primary MM cells [1]. Tilogotamab is a mixture of two non-competitive DR5-specific monoclonal immunoglobulin G1 (IgG1) antibodies, each featuring an E430G mutation in the Fc domain. This mutation enhances Fc-Fc interactions, leading to antibody hexamerization and subsequent FcγR-independent clustering of DR5 molecules [1]. |
Alias | Hx-DR5-01/05, HexaBody-DR5/DR5, GEN-1029, GEN1029 |
Cas No. | 2109731-10-2 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.